Allergy Associates of Utah | Murray, UT

Research site

(Unclaimed)

Location

6095 Fashion Boulevard, Suite 100, Murray, Utah, United States of America

Site insights

Top conditions

Top treatments

Remibrutinib

DX-2930

Omalizumab

CDX-0159

LOU064

Briquilimab

LTRA

Lebrikizumab

MSTT1041A

DUPIXENT®

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 17 total trials

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

The purpose of this trial is:1. to assess the efficacy, pharmacokinetics, and safety of remibrutinib vs. placebo in adolescents from 12 to \< 18 year...

Enrolling

Chronic Spontaneous Urticaria

Drug: placebo

Drug: LOU064 (blinded)

A Study of CDX-0159 in Patients With Chronic Inducible Urticaria

The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in...

Active, not recruiting

Chronic Inducible Urticaria

Drug: Matching Placebo

Biological: barzolvolimab

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension...

Enrolling

Chronic Inducible Urticaria

Drug: Remibrutinib

Other: Placebo

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participant...

Enrolling

Chronic Spontaneous Urticaria

Drug: LOU064 (blinded)

Drug: LOU064 (open label)

Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU) (BEACON)

This trial will be performed as a three-part dose escalating clinical trial where Parts 1 is open label and Parts 2 and 3 are randomized, double-blin...

Enrolling

Chronic Spontaneous Urticaria

Drug: Briquilimab

Other: Placebo

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria (CALM-CSU)

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urtica...

Enrolling

Chronic Spontaneous Urticaria

Drug: Placebo

Drug: Oral EP262

Locations recently updated

Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts

A study to evaluate the safety, efficacy and tolerability of remibrutinib at three doses versus placebo in adult participants who have a confirmed al...

Enrolling

Allergy, Peanut

Drug: placebo

Drug: remibrutinib